GNMSF (Genmab AS) Cyclically Adjusted Revenue per Share: $29.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNMSF Genmab AS GNMSF
92 GF Score
Price $282.00
GF Value $354.93
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Revenue per Share?

Genmab AS GNMSF -1.35% 92 Cyclically Adjusted Revenue per Share is $29.33 as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 92/100 and a GF Value™ of $354.93 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab AS's adjusted revenue per share for the three months ended in Mar. 2026 was $14.032. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $29.33 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Revenue Growth Rate was 26.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 29.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab AS was 43.30% per year. The lowest was 29.50% per year. And the median was 36.00% per year.

As of today (2026-07-18), Genmab AS's current stock price is $282.00. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $29.33. Genmab AS's Cyclically Adjusted PS Ratio of today is 9.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 45.79.


Genmab AS  (OTCPK:GNMSF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=282.00/29.33
=9.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 45.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab AS Cyclically Adjusted Revenue per Share Related Terms


Genmab AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Revenue per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.30 12.05 15.72 19.61 27.91

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.27 25.70 27.35 27.91 29.33

GNMSF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


GNMSF
92GF Score
Genmab AS GNMSF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.032/121.6800*121.6800
=14.032

Current CPI (Mar. 2026) = 121.6800.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.855 100.600 1.034
201609 0.889 100.200 1.080
201612 1.991 100.300 2.415
201703 0.582 101.200 0.700
201706 1.916 101.200 2.304
201709 0.811 101.800 0.969
201712 2.697 101.300 3.240
201803 1.814 101.700 2.170
201806 1.278 102.300 1.520
201809 1.502 102.400 1.785
201812 2.979 102.100 3.550
201903 1.443 102.900 1.706
201906 1.873 102.900 2.215
201909 2.350 102.900 2.779
201912 6.871 102.900 8.125
202003 2.003 103.300 2.359
202006 12.500 103.200 14.738
202009 4.124 103.500 4.848
202012 6.042 103.400 7.110
202103 3.777 104.300 4.406
202106 4.785 105.000 5.545
202109 5.454 105.800 6.273
202112 5.544 106.600 6.328
202203 4.821 109.900 5.338
202206 6.728 113.600 7.207
202209 8.195 116.400 8.567
202212 12.857 115.900 13.498
202303 6.302 117.300 6.537
202306 9.242 116.400 9.661
202309 10.131 117.400 10.500
202312 11.074 116.700 11.547
202403 9.233 118.400 9.489
202406 12.011 118.500 12.333
202409 12.810 118.900 13.110
202412 14.257 118.900 14.590
202503 11.183 120.200 11.321
202506 14.921 120.700 15.042
202509 16.464 121.600 16.475
202512 16.763 121.200 16.829
202603 14.032 121.680 14.032

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $29.33 mean?
Genmab AS (GNMSF) has a Cyclically Adjusted Revenue per Share of $29.33 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Revenue per Share too high?
Genmab AS's current Cyclically Adjusted Revenue per Share is $29.33. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Revenue per Share of $29.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Revenue per Share is $29.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $354.93, compared to a current price of $282.00 — trading 20.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $29.33. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Cyclically Adjusted Revenue per Share is $29.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $282.00 is trading 20.5% below its estimated GF Value™ of $354.93. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Cyclically Adjusted Revenue per Share: $29.33
  • GF Value™: $354.93 vs. price of $282.00 (20.5% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score

Get the complete analysis for GNMSF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$282.00
Price
$354.93
GF Value